{"schema_version":"1","generated_at":"2026-11-16T09:16:18.100Z","data_as_of":"2026-11-13","url":"https://www.findmykol.com/kol/roger-echols","json_url":"https://www.findmykol.com/kol/roger-echols/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"roger-echols","name":"Roger Echols","credential":"MD","title":"Principal Member","specialty":"Infectious Disease","specialty_raw":"Infectious Disease","therapeutic_area":"Infectious Disease","therapeutic_areas":["Infectious Disease"],"institution":"ID3C","institution_url":"https://www.findmykol.com/institution/id3c","city":"Easton","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1730443698","openalex":"A5111697149"},"summary":"Roger Echols is Principal Member at ID3C. OpenAlex indexes 172 publications with 7,300 citations (h-index 44); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.","overview":{"text":"Roger Echols, MD, is Principal Member at ID3C, LLC. The public record shows 172 publications with 7,300 citations (h-index 44), centered on Bronchitis, Bronchitis, Chronic. It also documents an investigator role on 2 registered clinical trials.","bullets":["Top research focus: Bronchitis","2 registered trials on ClinicalTrials.gov"],"generated_at":"2026-11-15"},"focus":{"indications":[{"label":"Bronchitis","therapeutic_area":"Infectious Disease","trials":1,"topics":0,"strength":3},{"label":"Bronchitis, Chronic","therapeutic_area":"Infectious Disease","trials":1,"topics":0,"strength":3},{"label":"Otitis","therapeutic_area":"Head & Neck","trials":1,"topics":0,"strength":3},{"label":"Otitis Media","therapeutic_area":"Head & Neck","trials":1,"topics":0,"strength":3},{"label":"Chronic Kidney Disease","therapeutic_area":"Nephrology","trials":0,"topics":0,"strength":1},{"label":"Cystic Fibrosis","therapeutic_area":"Respiratory","trials":0,"topics":0,"strength":1},{"label":"ESRD / Dialysis","therapeutic_area":"Nephrology","trials":0,"topics":0,"strength":1},{"label":"HIV","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1},{"label":"Prostate Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Sepsis / Serious Bacterial","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1},{"label":"Tuberculosis","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1}],"research_topics":["Bronchitis","Bronchitis, Chronic"],"works_with":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"Replidyne","trials":2,"payments":0,"mentions":2}]}},"scholarship":{"works_count":172,"cited_by_count":7300,"h_index":44,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT00276042","title":"A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media","phase":"PHASE2","status":"COMPLETED","role":"Investigator","sponsor":"Replidyne","source_url":"https://clinicaltrials.gov/study/NCT00276042","trial_url":"https://www.findmykol.com/trial/NCT00276042"},{"nct":"NCT00255983","title":"A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis","phase":"PHASE3","status":"TERMINATED","role":"Investigator","sponsor":"Replidyne","source_url":"https://clinicaltrials.gov/study/NCT00255983","trial_url":"https://www.findmykol.com/trial/NCT00255983"}],"source":"trials"},"payments":{"company_count":0,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1730443698","source":"payments"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019","year":2023,"journal":"Microbial Drug Resistance","source_url":"https://doi.org/10.1089/mdr.2022.0279","status":"verified"},{"title":"Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies","year":2022,"journal":"Clinical Infectious Diseases","source_url":"https://doi.org/10.1093/cid/ciac078","status":"verified"},{"title":"Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials","year":2022,"journal":"Microbial Drug Resistance","source_url":"https://doi.org/10.1089/mdr.2021.0180","status":"verified"},{"title":"All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","year":2021,"journal":"Expert Review of Anti-infective Therapy","source_url":"https://doi.org/10.1080/14787210.2022.2020099","status":"verified"},{"title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","year":2021,"journal":"Journal of Antimicrobial Chemotherapy","source_url":"https://doi.org/10.1093/jac/dkab280","status":"verified"}],"most_cited":{"total":172,"shown":5,"withheld":167,"rows":[{"title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","year":2020,"cited_by_count":828,"type":"article","source_url":"https://doi.org/10.1016/s1473-3099(20)30796-9"},{"title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","year":2020,"cited_by_count":475,"type":"article","source_url":"https://doi.org/10.1016/s1473-3099(20)30731-3"},{"title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","year":2018,"cited_by_count":418,"type":"article","source_url":"https://doi.org/10.1016/s1473-3099(18)30554-1"},{"title":"Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy","year":1998,"cited_by_count":248,"type":"article","source_url":"https://doi.org/10.1016/s0090-4295(98)00296-9"},{"title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016","year":2017,"cited_by_count":235,"type":"article","source_url":"https://doi.org/10.1128/aac.01968-17"}]},"source":"works"},"recognition":{"education":{"total":2,"shown":2,"rows":[{"value":"MD","source_url":"https://www.researchgate.net/profile/Roger-Echols","status":"provisional","collected_at":"2026-11-13"},{"value":"FIDSA","source_url":"https://www.researchgate.net/profile/Roger-Echols","status":"provisional","collected_at":"2026-11-13"}]},"roles":{"total":1,"shown":1,"rows":[{"value":"Principal Member, ID3C, LLC","source_url":"https://www.researchgate.net/profile/Roger-Echols","status":"provisional","collected_at":"2026-11-13"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Consultant at Shionogi","source_url":"https://www.researchgate.net/profile/Roger-Echols-2","status":"provisional","collected_at":"2026-11-13"}]}},"similar":[{"name":"Thomas Walsh","slug":"thomas-walsh","institution":"Cornell University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/thomas-walsh","json_url":"https://www.findmykol.com/kol/thomas-walsh/profile.json"},{"name":"Douglas Richman","slug":"douglas-richman","institution":"University of California San Diego","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/douglas-richman","json_url":"https://www.findmykol.com/kol/douglas-richman/profile.json"},{"name":"Henry Masur","slug":"henry-masur","institution":"National Institutes of Health","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/henry-masur","json_url":"https://www.findmykol.com/kol/henry-masur/profile.json"},{"name":"Vance Fowler","slug":"vance-fowler","institution":"Duke University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/vance-fowler","json_url":"https://www.findmykol.com/kol/vance-fowler/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-13"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-13"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}